The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary clinical testing of the lower-cost "generic" alternatives to biologic drugs that treat serious diseases. The agency said it is also planning initiatives to make it easier for biosimilars to be approved as interchangeable with brand-name biologics.
